NEW YORK--(BUSINESS WIRE)--
Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of
Margaret Valeur-Jensen, Ph.D. to the newly created position of General
Counsel, effective immediately. She will be responsible for providing
legal advice regarding the Company's commercial operations, research
activities, business development and compliance with industry standards.
Dr. Valeur-Jensen joins Retrophin from Seed Intellectual Property Law
Group PLLC. There, she served as Of Counsel in the Biotechnology,
Pharmaceuticals and Chemistry Group. Previously, she was Executive Vice
President and General Counsel of Neurocrine Biosciences, Inc., where she
was responsible for all patent and corporate practice including
management of patent portfolio and strategy, corporate partnering,
regulatory compliance, and public company issues. Earlier, she was
Associate General Counsel Business Law Group of Amgen Inc., where she
was responsible for licensing and corporate partnering, mergers and
acquisitions, clinical development, sales and marketing, regulatory
affairs, and real estate. Prior to joining Amgen, she was an associate
at Davis, Polk & Wardwell.
"The addition of Meg as General Counsel strengthens our management
team," said Stephen Aselage, Chief Executive Officer of Retrophin. "Her
deep legal expertise as it relates to the biopharmaceutical industry
will be vital as we enter the next phase of our transition and
accelerate the Company's growth."
"I'm delighted to join Retrophin at such an exciting time," said Dr.
Valeur-Jensen. "I look forward to working with the team to ensure
compliance as it maximizes commercial products, advances key pipeline
assets, and pursues business development opportunities."
Dr. Valeur-Jensen received her J.D. from Stanford University School of
Law. In addition, she was a Post-Doctoral Fellow at Harvard Medical
School in the Department of Genetics, as well as at Massachusetts
General Hospital in the Department of Molecular Biology. She received a
Ph.D. in Biochemistry and Molecular Biology from Syracuse University and
a B.A. in Biology from Skidmore College.
Retrophin also announced the grant of an inducement award to Ms.
Valeur-Jensen pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules in
connection with her employment with Retrophin. In connection with her
employment, Ms. Valeur-Jensen was granted an inducement award consisting
of 100,000 shares of restricted common stock, which will vest in full on
November 1, 2015. The restricted common stock award is subject to the
terms and conditions of Retrophin's 2014 Incentive Compensation Plan.
The award was granted as an inducement material to Ms. Valeur-Jensen's
employment pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
About Retrophin
Retrophin is a pharmaceutical company focused on the development,
acquisition and commercialization of drugs for the treatment of serious,
catastrophic or rare diseases for which there are currently no viable
options for patients. The Company's approved products include Chenodal®,
Thiola® and Vecamyl®, and its pipeline includes compounds for several
catastrophic diseases, including focal segmental glomerulosclerosis
(FSGS), pantothenate kinase-associated neurodegeneration (PKAN),
schizophrenia, infantile spasms, nephrotic syndrome and others. For
additional information, please visit www.retrophin.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and commercialization of
pharmaceutical products. Without limiting the foregoing, these
statements are often identified by the words "may", "might", "believes",
"thinks", "anticipates", "plans", "expects", "intends" or similar
expressions. No forward-looking statement can be guaranteed. You are
cautioned not to place undue reliance on these forward-looking
statements as there are important factors that could cause actual
results to differ materially from those in forward-looking statements,
many of which are beyond our control. The Company undertakes no
obligation to publicly update forward-looking statements, whether as a
result of new information, future events, or otherwise. Investors are
referred to the full discussion of risks and uncertainties as included
in the Company's filings with the Securities and Exchange Commission.
Retrophin, Inc.
Chris Cline, 646-564-3680
CFA, Manager
Investor
Relations
IR@retrophin.com
Source: Retrophin, Inc.
News Provided by Acquire Media